Impax Pharmaceuticals (IPXL) Announces Presentation of RYTARYTM (IPX066) (Carbidopa and Levodopa) Extended-Release Capsules Phase III and Open-Label Extension Data at the American Academy of Neurology 2013 Annual Meeting
3/19/2013 9:42:47 AM
More...
|
Impax Pharmaceuticals (IPXL) Fails to Win Approval for Parkinson's Drug
1/22/2013 7:47:01 AM
More...
|
Impax Pharmaceuticals (IPXL): FDA Extends Review on Rytary NDA
10/12/2012 7:33:10 AM
More...
|
Impax Pharmaceuticals Release: Data from ASCEND-PD Phase III Study of IPX066 to be Presented at the American Academy of Neurology Conference
4/18/2012 9:57:16 AM
More...
|
FDA Accepts Impax Pharmaceuticals NDA Filing for IPX066 for the Treatment of Idiopathic Parkinson’s Disease
2/23/2012 6:16:33 AM
More...
|
Impax Pharmaceuticals Gains Rights for US Sales of AstraZeneca PLC (AZN)'s Zomig; Paying $130 Million in 2012
2/1/2012 7:19:51 AM
More...
|
Impax Pharmaceuticals Submits New Drug Application for IPX066 in Parkinson’s Disease
12/21/2011 1:47:53 PM
More...
|
Impax Pharmaceuticals Initiates Phase IIb Trial of IPX159 in Restless Legs Syndrome
12/19/2011 9:39:35 AM
More...
|
Impax Pharmaceuticals Completes Enrollment in ASCEND-PD Phase III Trial of IPX066 in Parkinson’s Disease
7/26/2011 7:07:15 AM
More...
|
Impax Pharmaceuticals Awarded Michael J. Fox Foundation Grant for Ongoing Research of IPX066 for Parkinson’s Disease
7/14/2011 9:06:40 AM
More...
|
|